These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31875805)

  • 1. Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients.
    Law YM; Nandi D; Molina K; Gambetta K; Daly KP; Das B
    Cardiol Young; 2020 Jan; 30(1):107-113. PubMed ID: 31875805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience.
    Kleiboeker HL; Prom A; Paplaczyk K; Myers CN
    Ann Pharmacother; 2024 Sep; 58(9):947-955. PubMed ID: 37994573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts.
    Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD
    Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
    Wijnsma KL; Duineveld C; Wetzels JFM; van de Kar NCAJ
    Pediatr Nephrol; 2019 Nov; 34(11):2261-2277. PubMed ID: 30402748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electron-dense deposit in renal transplant patients on eculizumab may be drug-derived.
    Brealey JK; Cassidy J
    Ultrastruct Pathol; 2016; 40(1):2-6. PubMed ID: 26512451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
    Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
    Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of complement inhibition in kidney transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Frémeaux-Bacchi V
    Br Med Bull; 2017 Dec; 124(1):5-17. PubMed ID: 29069327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab for Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience.
    Yelken B; Arpalı E; Görcin S; Kocak B; Karatas C; Demiralp E; Turkmen A
    Transplant Proc; 2015; 47(6):1754-9. PubMed ID: 26293046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab for antibody-mediated rejection in heart transplantation: A case-control study.
    Kittleson MM; Patel N; Chang DH; Kransdorf EP; Kobashigawa JA; Patel JK
    Clin Transplant; 2021 Dec; 35(12):e14454. PubMed ID: 34402096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients.
    Jordan SC; Choi J; Kahwaji J; Vo A
    Transplant Proc; 2016 Apr; 48(3):806-8. PubMed ID: 27234741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation.
    Wang H; Arp J; Liu W; Faas SJ; Jiang J; Gies DR; Ramcharran S; Garcia B; Zhong R; Rother RP
    J Immunol; 2007 Oct; 179(7):4451-63. PubMed ID: 17878341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases.
    Tan EK; Bentall A; Dean PG; Shaheen MF; Stegall MD; Schinstock CA
    Transplantation; 2019 Nov; 103(11):2397-2404. PubMed ID: 30801549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab for Prevention of Antibody-Mediated Rejection in Blood Group-Incompatible Renal Transplantation.
    West-Thielke P; Progar K; Campara M; Jasiak N; Gallon L; Tang I; Spaggiari M; Tzvetanov I; Benedetti E
    Transplant Proc; 2018; 50(1):66-69. PubMed ID: 29407333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement inhibition as potential new therapy for antibody-mediated rejection.
    Eskandary F; Wahrmann M; Mühlbacher J; Böhmig GA
    Transpl Int; 2016 Apr; 29(4):392-402. PubMed ID: 26474721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab Is Safe and Effective as a Long-term Treatment for Protein-losing Enteropathy Due to CD55 Deficiency.
    Kurolap A; Eshach Adiv O; Hershkovitz T; Tabib A; Karbian N; Paperna T; Mory A; Vachyan A; Slijper N; Steinberg R; Zohar Y; Mevorach D; Baris Feldman H
    J Pediatr Gastroenterol Nutr; 2019 Mar; 68(3):325-333. PubMed ID: 30418410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
    Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
    Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.